Glucagon · source year
11 selected, source-linked Glucagon records carrying a 2025 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
11 selected records.
2 represented types.
11 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06921824 at 2026-07-30T18:18:33.507Z. Its registry update date was 2025-12-24, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07300982 at 2026-07-30T18:18:33.509Z. Its registry update date was 2025-12-24, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06588504 at 2026-07-30T18:18:33.514Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Regulatory
The Federal Register published notice 2025-22131, attributed to FDA and its parent HHS department, on 2025-12-05. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.
Source: Federal Register via GovInfo ↗
Regulatory
The Federal Register published notice 2025-20548, attributed to FDA and its parent HHS department, on 2025-11-21. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Tirzepatide.
Source: Federal Register via GovInfo ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06872060 at 2026-07-30T18:20:54.427Z. Its registry update date was 2025-10-03, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 218813 with status AP dated 2025-09-15, and names glucagon among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory
DailyMed lists Structured Product Labeling version 1 for the reviewed Glucagon label family with a published date of 2025-08-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03241706 at 2026-07-30T18:24:37.180Z. Its registry update date was 2025-07-25, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 214457 with status AP dated 2025-07-22, and names glucagon among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02078726 at 2026-07-30T18:24:37.187Z. Its registry update date was 2025-07-03, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗